{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-096709","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2026-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.957594+00:00","generated_at":"2026-05-15T18:49:03.974709+00:00","sec_items":["1.01","2.02","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Solid Biosciences raises ~$240M in private placement; prelim cash ~$188M","bullets":["Gross proceeds ~$240M from 14.97M shares at $5.61 and 27.81M pre-funded warrants at $5.609.","Preliminary cash, equivalents and securities ~$187.9M as of Dec 31, 2025 (unaudited).","Net proceeds extend runway into H1 2028; funds pipeline development, BD, and G&A.","Investors include Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, and others.","Private placement expected to close March 9, 2026; Leerink and Citi lead placement agents."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-096709","json":"https://secwatch.observer/filing/0001193125-26-096709.json","markdown":"https://secwatch.observer/filing/0001193125-26-096709.md","text":"https://secwatch.observer/filing/0001193125-26-096709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526096709/0001193125-26-096709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526096709/d81855d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:49:03.974709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e58e3a06a2fa9815a1aafa41ab9d438a166023c","claim":"Solid Biosciences Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at approximately $240.0 million (effective 2026-03-06).","evidence_excerpt":"On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a price of $5.61 per share, and, to investors who so choose in lieu of Shares, pre-funded warrants to purchase 27,807,482 shares of the Company’s common stock (the “ Pre-Funded Warrants ”), at a price of $5.609 per Pre-Funded Warrant (the “ Private Placement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526096709/0001193125-26-096709-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional accredited investors"},{"label":"Value","value":"approximately $240.0 million"},{"label":"Effective","value":"2026-03-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}